Bennett Selby Investments LP Purchases 2,074 Shares of Novo Nordisk A/S (NYSE:NVO)

Bennett Selby Investments LP lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 7.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 28,225 shares of the company’s stock after purchasing an additional 2,074 shares during the period. Novo Nordisk A/S accounts for approximately 1.0% of Bennett Selby Investments LP’s portfolio, making the stock its 21st biggest holding. Bennett Selby Investments LP’s holdings in Novo Nordisk A/S were worth $2,428,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in NVO. Raymond James & Associates grew its stake in shares of Novo Nordisk A/S by 1.0% in the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC raised its holdings in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares in the last quarter. International Assets Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. LPL Financial LLC increased its position in shares of Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares during the period. Finally, Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at $98,765,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on NVO. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $87.94 on Friday. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The stock has a market capitalization of $394.65 billion, a PE ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock’s fifty day moving average is $95.62 and its 200-day moving average is $115.55.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.